Risk of Repeated Pseudo-Allergic Reactions Related to Non-Steroidal Anti-Inflammatory Drugs in Chonburi Hospital
Article Sidebar
Main Article Content
Abstract
Objective: To identify risk of repeated pseudo-allergic reactions (PAR) related to non-steroidal anti-inflammatory drugs (NSAIDs). Method: The research design was a cross-sectional study retrospectively collecting adverse drug reaction (ADR) reports related to NSAIDs in Chonburi hospital during January 1, 2011 to December 31, 2016. The study identified associations between NSAID groups and ADRs. Results: The study identified 493 reports of ADRs related to NSAIDs from the total of 18,674 reports (2.64%). There were 281 reports on angioedema and anaphylaxis symptoms (57% of the total ADR reports related to NSAIDs). Arilpropionic acids and hetero acetic acids were the top suspected drug in 272 and 104 reports (55.2% and 23.1% of the total ADR reports related to NSAIDs, respectively). NSAID structures were associated with cutaneous ADR (P<0.05). There were 49 reports of pseudo drug allergy (9.34% of the total ADR reports related to NSAIDs). First occurrence of allergy was most prevalent in hetero acetic acids with 10 reports (43.5% of the first occurrence of allergy), especially diclofenac. Second hypersensitivity following the first one was related most to arilpropionic acids (ibuprofen and naproxen) (53.8%). There were 28 reports on cutaneous ADR for Cox II inhibitor group (celecoxib and etoricoxib) and 4 of these were PAR (8.16% of total reported PAR). Conclusion: Rate of PAR was about 10% of NSAIDs allergy. To decrease the risk of PAR, health care provider should thoroghly review history of ADR and intensively monitor ADRs in patients receiving NSAIDs.
Article Details
ผลการวิจัยและความคิดเห็นที่ปรากฏในบทความถือเป็นความคิดเห็นและอยู่ในความรับผิดชอบของผู้นิพนธ์ มิใช่ความเห็นหรือความรับผิดชอบของกองบรรณาธิการ หรือคณะเภสัชศาสตร์ มหาวิทยาลัยสงขลานครินทร์ ทั้งนี้ไม่รวมความผิดพลาดอันเกิดจากการพิมพ์ บทความที่ได้รับการเผยแพร่โดยวารสารเภสัชกรรมไทยถือเป็นสิทธิ์ของวารสารฯ
References
2. Kongkaew C, Noyce PR, Ashcroft DM. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann Pharmacother. 2008;42:1017-25.
3. Aun MV, Blanca M, Garro LS, Ribeiro MR, Kalil J, Motta AA, et al. Nonsteroidal anti-inflammatory drugs are major causes of drug-induced anaphy laxis. J Allergy Clin Immunol Pract. 2014;2:414-20.
4. Techapornroong M, Akrawinthawong K, Cheungpa sitporn W, Ruxrungtham K. Anaphylaxis: a ten years inpatient retrospective study. Asian Pac J Allergy Immunol. 2010;28:262-9.
5. Helbling A, Hurni T, Mueller U, Pichler W. Incidence of anaphylaxis with circulatory symptoms: a study over a 3‐year period comprising 940000 inhabitants of the Swiss Canton Bern. Clin Exp Allergy. 2004; 34: 285-90.
6. Benkirane R, Pariente A, Achour S, Ouammi L, Azzouzi A, Soulaymani R. Prevalence and preventa bility of adverse drug events in a teaching hospital: a cross-sectional study. East Mediterr Health J. 2009;15:1145-55.
7. Demoly P, Bousquet J. Epidemiology of drug allergy. Curr Opin Allergy Clin Immunol. 2001;1:305-10.
8. Zhang B, Li Q, Shi C, Zhang X. Drug-induced pseudoallergy: a review of the causes and mecha nisms. Pharmacology. 2018;101: 104-10.
9. Wang H, Wang H, Liu Z. Agents that induce pseudo-allergic reaction. Drug Discov Ther. 2011;5: 211-9.
10. Demoly P, Lebel B, Messaad D, Sahla H, Rongier M, Daures J, et al. Predictive capacity of histamine release for the diagnosis of drug allergy. Allergy. 1999;54:500-6.
11. Weberschock TB, Müller S-M, Boehncke S, Boehncke W-H. Tolerance to coxibs in patients with intolerance to non-steroidal anti-inflammatory drugs (NSAIDs): a systematic structured review of the literature. Arch Dermatol Res. 2007;299:169-75.
12. Simon RA. NSAIDs (including aspirin): Allergic and pseudoallergic reactions 2015 [online]. 2015 [cited July 12, 2019]. Available from: www.uptodate.com /contents/nsaids-including-aspirin-allergic-and-pseu doallergic-reactions.
13. Health product vigilance center (HPVC). Sponta neous reports of adverse drug reactions 2017. Nonthaburi: Food and Drug Administration, Ministry of Public Health; 2018.
14. Tan V, Gerez I, Van HB. Prevalence of drug allergy in Singaporean children. Singapore Med J. 2009; 50: 1158-61.
15. Luanghirun P, Tanaboriboon P, Mahissarakul P, Lertvivatpong N. Prevalence and associated factors of regular nonsteroidal anti-inflammatory drugs used in a rural community, Thailand. Glob J Health Sci. 2017; 9: 58.
16. Wehling M. Non-steroidal anti-inflammatory drug use in chronic pain conditions with special empha sis on the elderly and patients with relevant comor bidities: management and mitigation of risks and adverse effects. Eur J Clin Pharmacol 2014; 70: 1159-72.
17. Kowalski M, Makowska J, Blanca M, Bavbek S, Bochenek G, Bousquet J, et al. Hypersensitivity to nonsteroidal anti‐inflammatory drugs (NSAIDs)–classification, diagnosis and management: review of the EAACI/ENDA# and GA2LEN/HANNA. Allergy. 2011;66: 818-29.
18. Van Puijenbroek EP, Egberts AC, Meyboom RH, Leufkens HG. Different risks for NSAID-induced anaphylaxis. Ann Pharmacother. 2002;36:24-9.
19. Sylvia L, DiPiro J. Allergic and pseudoallergic drug reactions. Pharmacotherapy: A pathophysiologic approach. 8th ed. New York: McGraw-Hill; 2011.
20. Fontaine C, Bousquet PJ, Demoly P. Anaphylactic shock caused by a selective allergy to celecoxib, with no allergy to rofecoxib or sulfamethoxazole. J Allergy Clin Immunol. 2005;115:633-4.
21. Habki R, Vermeulen C, Bachmeyer C, Charoud A, Mofredj A. Anaphylactic shock induced by celecoxib. Ann Med Interne (Paris). 2001;152:355.
